KEYNOTE-826研究是一项在全球19个国家的151个癌症治疗中心进行的多中心、随机、Ⅲ期临床试验。在首次中期分析时,帕博利珠单抗联合铂类化疗(加或不加贝伐珠单抗)作为一线治疗,显著改善了PD-L1阳性(CPS≥1)的持续性、复发或转移性宫颈癌...
KEYNOTE-826研究是一项在全球19个国家的151个癌症治疗中心进行的多中心、随机、Ⅲ期临床试验。在首次中期分析时,帕博利珠单抗联合铂类化疗(加或不加贝伐珠单抗)作为一线治疗,显著改善了PD-L1阳性(CPS≥1)的持续性、复发或转移性宫颈癌患者的OS和PFS(主要研究终点)(OSHR0.64,95%CI 0.50-0.81,P<0.001;PFSHR0.62,...
在2022年美国妇科肿瘤学会(SGO)年会上,III期KEYNOTE-826试验(NCT03635567)的患者报告结局(PRO)结果公布,这项结果支持帕博利珠单抗+化疗±贝伐珠单抗应用于持续性、复发性或转移性宫颈癌患者。 KEYNOTE-826研究将符合条件的患者以1:1的比例...
KEYNOTE-826 (NCT03635567) is a phase 3, randomized, double-blind, multinational study designed to evaluate the efficacy and tolerability of CT with or without pembrolizumab and/or bevacizumab in the first-line setting. Trial design Eligible patients with recurrent, persistent, or metastatic cervical...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, met its overall sur...
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Su...
In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-line metastatic cervical cancer regardless of tumor PD-L1 expression who had...
We report the results of a window-of-opportunity phase 2 trial using neoadjuvant nivolumab + ipilimumab followed by standard chemoradiation therapy (RTCT) in cervical squamous cell carcinoma pts using the CD8+/FOXP3+ ratio as a surrogate marker of immune checkpoint blocka...
Background In KEYNOTE-826 (NCT03635567), pembrolizumab plus chemotherapy (±bevacizumab) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with persistent, recurrent, or metastatic cervical cancer. This exploratory analysis examined outcomes in patient subgroups ...
In KEYNOTE-826, when KEYTRUDA was administered in combination with paclitaxel and cisplatin or paclitaxel and carboplatin, with or without bevacizumab (n=307), to patients with persistent, recurrent, or first-l...